The global rosacea drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Rosacea is a common skin disease, which causes redness and visible blood vessels on the face. It commonly affects middle-aged women who have fair skin. Although there is no cure for rosacea, treatments can control and reduce the signs and symptoms associated with the disease. Rosacea is a condition diagnosed by symptoms, such as facial flushing, coarseness of skin, and an inflammatory papulopustular eruption resembling acne. The major factor that is expected to fuel the market growth is that with rising prevalence, the awareness among the physicians and societies has also increased, which further drives the demand of this market during the forecast period. Furthermore, the global market for rosacea drugs is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape.
The global rosacea drugs market analysis includes some of the key market players such as Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in June 2021, Teva Announces the U.S. launch of its generic version of SOOLANTRA (ivermectin) Cream, 1% for once-daily treatment of Rosacea.
Market Coverage
Competitive Landscape: Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Rosacea Drugs Market by Segment
By Type
• Topical
• Oral
By Application
• Drugs Stores
• Hospital
• Other
Global Rosacea Drugs Market by Region
North America
Europe
Asia-Pacific
Rest of the World